shutterstock_1384219187_picturedesignswiss

PictureDesignSwiss / Shutterstock.com

18 March 2021AmericasMuireann Bolger

Biogen sues Teva over MS generic

A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity (diroximel fumarate), according to a lawsuit filed by Biogen and Alkermes.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

English High Court finds Bayer patent obvious in win for Teva

11 October 2021 The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.

Groups urge Fed Circ to rehear Biogen patent case

18 January 2022 Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

More on this story

English High Court finds Bayer patent obvious in win for Teva

11 October 2021 The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.

Groups urge Fed Circ to rehear Biogen patent case

18 January 2022 Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

More on this story

English High Court finds Bayer patent obvious in win for Teva

11 October 2021 The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.

Groups urge Fed Circ to rehear Biogen patent case

18 January 2022 Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?